Archive for the ‘China Medicine Corporation CHME’ Category

China Medicine Corporation (CHME.OB) Reports Surge in Second Quarter Profit

Wednesday, August 13th, 2008

China Medicine Corporation (CHME.OB), a developer and distributor of pharmaceuticals and nutritional supplements in China, reported strong second quarter financial results this morning. Revenues increased 40.8% year over year to $11.6 million, compared to $8.3 million in Q2 2007. Net income soared 118.8% to $2.5 million, or 16 cents per share, vs. $1.1 million, or 8 cents per share a year ago. No analysts currently cover the stock.

Sales increased across the entire breadth of the company’s pharmaceutical portfolio. “We are pleased to report strong revenue growth driven by an increase in sales of pharmaceutical products through exclusive nationwide and regional distribution rights, competitive pricing, timely delivery of products and excellent after-sales customer service” commented Mr. Senshan Yang, Chairman and CEO of China Medicine. “Based on our outstanding first half 2008 performance, we feel confident that we will meet our guidance of 25%-35% revenue growth and 30%-35% gross margins for fiscal 2008. In addition, based on our strong second quarter profitability, we expect to exceed our net income guidance of 20%-22% for 2008.”

China Medicine received a patent during the quarter for recombinant aflatoxin-detoxifizyme (rADTZ) in Australia that is valid through January 13, 2025. rADTZ can be used as an additive to remove aflatoxins, potential cancer-causing agents, from animal feed and other food products. The Company has applied for rADTZ patents in 13 other jurisdictions. “The entrance of rADTZ in the animal feed industry is relatively easy since we will only need approval from the Department of Agriculture in China, which is in contrast to entering the food industry, where the process might take years,” said Mr. Yang. “Therefore, our target market is China’s entire feed industry, which is approximately RMB 274.2 billion ($39.8 billion, 1 RMB = $0.145). In the next three years, we hope rADTZ will capture 20% of the animal feed market,” said Mr. Yang.

Shares of CHME, which closed at $2.00 yesterday, sell for less than the company’s tangible book value. With 15.2 million shares outstanding, CHME has a market cap of $30.4 million, while tangible net assets now exceed $35.7 million. Through the second quarter, CHME now has a trailing twelve-month P/E of 3.1. The company has zero long-term debt. The upcoming third quarter is seasonally the company’s strongest.

Let us hear your thoughts below:

China Medicine Corporation (CHME) is “One to Watch”

Thursday, July 10th, 2008

China Medicine Corp., operating in the Wholesale Trade sector and established in 2005 as Lounsberry Holdings III, Inc., is a Delaware-registered company which in 2006 acquired Guangzhou Konzern Medicine Co., Ltd as its wholly owned subsidiary, and subsequently changed its name to China Medicine Corp.

Operating in the People’s Republic of China, the company distributes both licensed, prescription pharmaceuticals and over-the-counter (OTC) remedies. Their OTC remedies include Chinese herbs and traditional Chinese medications made from these herbs, as well as nutritional and dietary supplements and medical instruments. The total distribution encompasses more than 2,000 products and product lines.

China Medicine Corp. also engages in proprietary research and development of new drugs with the intent of creating products and intellectual properties for sale. The short term focus is on nutritional supplements, while the mid-term focus is on prescription and OTC drugs. The company’s ultimate goal is to develop traditional Chinese medicines which can prevent or alleviate cancerous tumors.

The company currently has four patents registered with the PRCs State Food and Drug Administration (SFDA) covering production protocols, and seven other patents awaiting SFDA approval. One of the company’s products is Iopamidol, a CT-contrast dye. Another is SonoVue, a diagnostic imaging agent containing sulfur hexafluoride used in ultrasound testing. Combined with its superior R&D, China Medicine Corp. actively seeks vertically integrated acquisitions focused on pharmaceutical manufacturing companies.

China Medicine Corp. maintains an extensive sales network which is currently expanding into the more rural areas of Guangdong province. Elsewhere, the company distributes to 28 provinces in China, including more than 300 hospitals, 500 medical/pharmaceutical companies and 1,800 drugstores. All of the company’s sales and marketing personnel are responsible not only for initial sales but for after-sale services as well, including follow-up visits with hospitals and customers, providing the sort of customer satisfaction and feedback that guarantees repeat sales and satisfied referrals.

China Medicine Corp. intends, with the help of its superb sales team, experienced management, advanced technology and dedicated R&D team, to become a leader in China’s pharmaceutical industry, delivering benefits to consumers and significant returns to shareholders.

Let us hear your thoughts: China Medicine Corp. Message Board

China Medicine (CHME.OB) Reports 54% Increase in Q1 Net Income

Monday, May 12th, 2008

China Medicine (CHME.OB), a developer and distributor of prescription pharmaceuticals and traditional Chinese medicines in the People’s Republic of China, today reported solid first quarter 2008 results. Revenues increased 39% year over year, rising to $7.1 million, in what is seasonally the company’s slowest quarter. Net income improved 54% to $1.2 million or 8 cents per share vs. prior year results.

Chairman and CEO Senshan Yang said, “We are very pleased with the healthy performance of our sales of prescription and over-the-counter medicines as well as our traditional Chinese medicines. This increase in revenues was attributed to the expansion of our distribution network to rural areas in Guangdong Province and the increase in provincial distribution rights through the online bidding system last quarter.”

Sales actually declined 55% sequentially from $16.1 million in the fourth quarter of 2007. Hospitals and pharmaceutical companies in China generally beef up their inventories at year-end ahead of the Chinese New Year holidays, so the company’s first quarter revenues are typically the lowest of the fiscal year.

The company offered full-year 2008 guidance, predicting a 25-35% increase in revenues over 2007 ($42.1 million) and a 20-22% increase in net income over last year ($6.9 million). Shares of CHME.OB closed 11.3% lower at $2.60 and have traded in a range of $1.55 – $4.48 during the past year. With 15.3 million shares outstanding, CHME.OB has a market cap of $40 million.

Let us hear your thoughts below:

China Medicine Corporation (CHME) Demands its Spot in the World’s Pharmaceutical Market

Wednesday, December 12th, 2007

China Medicine Corporation (NASDAQ: CHME) (CMC) was established in 2005 with the goal to become a leading, research-driven pharmaceutical company dedicated to the discovery, development, manufacturing and distribution of pharmaceutical and nutritional supplement products throughout China. To fulfill this mission, CMC acquired Guangzhou Konzern Medicine Co., Ltd. in 2007.

Through its wholly-owned subsidiary, Guangzhou Konzern, CMC now distributes about 1,500 pharmaceutical products in the People’s Republic of China to a network of nearly 300 hospitals, 500 pharmaceutical companies and 1,700 drug stores. Not only does the company offer prescription and over-the-counter pharmaceutical products, traditional Chinese medicines, dietary supplements and medical instruments, it is also involved in the sale of medical formula and the development of new products.

CMC’s cocktail of experience in Western management skills, a large distribution network, advanced technology, and capital resources creates an undeniable presence on the global pharmaceutical market. The Chinese healthcare industry is expected to become one of the largest in the world, and according to the company’s Web site, “CMC aims to take advantage of the conditions within the industry and the surging demand for pharmaceutical and nutritional supplements products fueling economic growth.”

Let us hear your thoughts: China Medicine Corporation Message Board

China Medicine Corp.’s (CHME) Growth Matches Red-Hot Chinese Economy

Monday, January 1st, 2007

E-mail

China’s economy is booming and the pharmaceutical industry is keeping pace within the country. The country’s pharmaceutical market is expected to be the world’s fifth largest by 2010 and the largest by 2050. China has already captured a significant market share of the world’s pharmaceutical market and will likely continue to grow. The Chinese drug market is currently valued at $18.5 billion reporting a 14% increase in annual growth. By 2010 it is expected that drug sales will rise to $28 billion. China Medicine Corp. is already capitalizing on these developments, as the company registered improved results for the first half of 2007 when compared to 2006. The numbers speak for themselves: the revenue for the first six months of 2007 reached $13.4 million meaning a 70.2 % increase over the same period in 2006. The result of company operations registered even higher growth. In comparison with 2006 the operating income grew by 192.5% for the first half of 2007 to reach $2.4 million. Net income increased from $0.6 million for the first six months of 2006 to $1.9 million for the same period of 2007, representing a 240% growth rate. The improvement of the Company’s results is even more substantial if one considers that the second half of the year is generally the strongest compared to the first one. The pharmaceutical industry usually experiences an increased demand in the second part of the year, a trend that will allow CHME to capitalize on and potentially raise its revenue forecasts. Moreover, CHME recently received a grant from the Guangdong Province for its ADTZ project in order to support the product commercialization. The growing Chinese economy and the increasing life span of Chinese citizens, should work to positively impact the medical and pharmaceutical industry as a whole.

About China Medicine Corporation (OTCBB: CHME)

China Medicine is a distributor of medical products, traditional pharmaceutical medicines, traditional Chinese medicines, Chinese herbs and dietary supplements to over 28 provinces and 2,500 customers within China. The Company sells more than 1,500 products and is actively building a pipeline of proprietary traditional and Chinese herbal remedy products targeting oncology, high blood pressure and the removal of Aflatoxins from food and animal feed.